Salinomycin promotes anoikis and decreases the CD44+/CD24- stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  An, Hyunsook ^a   Kim, Ji Young ^a   Oh, Eunhye ^a   Lee, Nahyun ^a   Cho, Youngkwan ^a   Seo, Jae Hong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CD24 ANTIGEN; GELATINASE A; GELATINASE B; HERMES ANTIGEN; INTERLEUKIN 6; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SALINOMYCIN; STAT3 PROTEIN; TYROSINE; CD22 ANTIGEN; IL6 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; PYRAN DERIVATIVE; STAT3 PROTEIN, HUMAN; TUMOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANOIKIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER STEM CELL; CELL DEATH; CELL MIGRATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; BIOSYNTHESIS; BREAST TUMOR; GENETICS; MALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANOIKIS; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PYRANS; SIALIC ACID BINDING IG-LIKE LECTIN 2; STAT3 TRANSCRIPTION FACTOR;

EID: 84951867374     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141919     Document Type: Article

References (48)

1. Chavez KJ, Garimella SV, Lipkowitz S (2010) Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 32: 35-48. doi: 10.3233/BD-2010-0307 PMID: 21778573
2. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767. doi: 10.1172/JCI45014 PMID: 21633166
3. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, et al. (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest 121: 2723-2735. doi: 10.1172/JCI44745 PMID: 21633165
4. Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, et al. (2012) CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43: 364-373. doi: 10.1016/j.humpath.2011.05.005 PMID: 21835433
5. Ma F, Li H, Wang H, Shi X, Fan Y, et al. (2014) Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett 353: 153-159. doi: 10.1016/j.canlet.2014.06.022 PMID: 25130168
6. Munoz P, Iliou MS, Esteller M (2012) Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol 6: 620-636. doi: 10.1016/j.molonc.2012.10.006 PMID: 23141800
7. Baccelli I, Trumpp A (2012) The evolving concept of cancer and metastasis stem cells. J Cell Biol 198: 281-293. doi: 10.1083/jcb.201202014 PMID: 22869594
8. Grotenhuis BA, Wijnhoven BP, van Lanschot JJ (2012) Cancer stem cells and their potential implications for the treatment of solid tumors. J Surg Oncol 106: 209-215. doi: 10.1002/jso.23069 PMID: 22371125
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988. PMID: 12629218
10. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, et al. (2011) Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 64: 937-946. doi: 10.1136/jcp.2011.090456 PMID: 21680574
11. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511. PMID: 15994920
12. Kruyt FA, Schuringa JJ (2010) Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy. Biochem Pharmacol 80: 423-430. doi: 10.1016/j.bcp.2010.04.010 PMID: 20394737
13. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270. PMID: 12756227
14. Cheng HL, Su SJ, Huang LW, Hsieh BS, Hu YC, et al. (2010) Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis-involvement of STAT3 and RhoA activation. Mol Cancer 9: 126. doi: 10.1186/1476-4598-9-126 PMID: 20507639
15. Gilmore AP (2005) Anoikis. Cell Death Differ 12 Suppl 2: 1473-1477. PMID: 16247493
16. Paoli P, Giannoni E, Chiarugi P (2013) Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 1833: 3481-3498. doi: 10.1016/j.bbamcr.2013.06.026 PMID: 23830918
17. Guadamillas MC, Cerezo A, Del Pozo MA (2011) Overcoming anoikis-pathways to anchorage-independent growth in cancer. J Cell Sci 124: 3189-3197. doi: 10.1242/jcs.072165 PMID: 21940791
18. Fofaria NM, Srivastava SK (2014) Critical role of STAT3 in melanoma metastasis through anoikis resistance. Oncotarget 5: 7051-7064. PMID: 25216522
19. Fofaria NM, Srivastava SK (2015) STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. Carcinogenesis 36: 142-150. doi: 10.1093/carcin/bgu233 PMID: 25411359
20. Kim SY, Kang JW, Song X, Kim BK, Yoo YD, et al. (2013) Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal 25: 961-969. doi: 10.1016/j.cellsig.2013.01.007 PMID: 23333246
21. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, et al. (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12: 20-28. PMID: 16397019
22. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, et al. (2007) Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9: R32. PMID: 17531096
23. Watson CJ, Miller WR (1995) Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71: 840-844. PMID: 7710952
24. Burke WM, Jin X, Lin HJ, Huang M, Liu R, et al. (2001) Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20: 7925-7934. PMID: 11753675
25. Devarajan E, Huang S (2009) STAT3 as a central regulator of tumor metastases. Curr Mol Med 9: 626-633. PMID: 19601811
26. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, et al. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 104: 7391-7396. PMID: 17463090
27. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659. doi: 10.1016/j.cell.2009.06.034 PMID: 19682730
28. Verdoodt B, Vogt M, Schmitz I, Liffers ST, Tannapfel A, et al. (2012) Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species. PLoS One 7: e44132. doi: 10.1371/journal.pone.0044132 PMID: 23028492
29. Ketola K, Hilvo M, Hyotylainen T, Vuoristo A, Ruskeepaa AL, et al. (2012) Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer 106: 99-106. doi: 10.1038/bjc.2011.530 PMID: 22215106
30. Zhou J, Li P, Xue X, He S, Kuang Y, et al. (2013) Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species. Toxicol Lett 222: 139-145. doi: 10.1016/j.toxlet.2013.07.022 PMID: 23916687
31. Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C (2010) Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 394: 1098-1104. doi: 10.1016/j.bbrc.2010.03.138 PMID: 20350531
32. Wang F, He L, Dai WQ, Xu YP, Wu D, et al. (2012) Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One 7: e50638. doi: 10.1371/journal.pone.0050638 PMID: 23284640
33. Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, et al. (2009) Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia 11: 583-593. PMID: 19484147
34. Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J, Stark GR (2013) STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci U S A 110: 16975-16980. doi: 10.1073/pnas.1315862110 PMID: 24082147
35. Sansone P, Bromberg J (2012) Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30: 1005-1014. doi: 10.1200/JCO.2010.31.8907 PMID: 22355058
36. Miklossy G, Hilliard TS, Turkson J (2013) Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 12: 611-629. doi: 10.1038/nrd4088 PMID: 23903221
37. Leslie K, Lang C, Devgan G, Azare J, Berishaj M, et al. (2006) Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 66: 2544-2552. PMID: 16510571
38. Carpenter RL, Lo HW (2014) STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel) 6: 897-925.
39. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11: 558-572. doi: 10.1038/nrc3090 PMID: 21734724
40. Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23: 4215-4224. PMID: 15961768
41. Koo KH, Kim H, Bae YK, Kim K, Park BK, et al. (2013) Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2. Cell Death Dis 4: e693. doi: 10.1038/cddis.2013.223 PMID: 23807222
42. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174. PMID: 11990853
43. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, et al. (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104: 16158-16163. PMID: 17911267
44. Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, et al. (2014) Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer 14: 317. doi: 10.1186/1471-2407-14-317 PMID: 24886434
45. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567. doi: 10.1016/j.stem.2007.08.014 PMID: 18371393
46. Lin L, Hutzen B, Lee HF, Peng Z, Wang W, et al. (2013) Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells. PLoS One 8: e82821. doi: 10.1371/journal.pone.0082821 PMID: 24376586
47. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, et al. (2009) Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev 18: 1093-1108. doi: 10.1089/scd.2009.0113 PMID: 19480567
48. Lin L, Hutzen B, Li PK, Ball S, Zuo M, et al. (2010) A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 12: 39-50. PMID: 20072652